Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:30:16.631Z.
Calculation as of: 2026-10-06T18:30:16.631Z.
Quote observation: 2026-10-06T18:30:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f621ea2a381ac0066d385c57ed104ff22630177ee14cd635e65ed0429d7856c2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Aclaris Therapeutics, Inc.
Market Cap
$521.64M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$524.77M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$533.82M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$536.29M
EV/EBITDA Ratio
N/A
TTM Avg
144.36x
3Y Avg
144.36x
5Y Avg
144.36x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $521.64M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $525.52M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $524.77M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $522.16M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $533.02M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $533.82M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $536.29M | N/A | 144.36x | 144.36x | 144.36x |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $512.21M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $541.32M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
